Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow

Blood

Volumn 117, Issue 2, 2011, Pages 651-660

  Cosemans, Judith M E M ^a   Schols, Saskia E M ^a   Stefanini, Lucia ^b   De Witt, Susanne ^a   Feijge, Marion A H ^a   Hamulyák, Karly ^a   Deckmyn, Hans ^c   Bergmeier, Wolfgang ^b   Heemskerk, Johan W M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN G; CYCLIC AMP; GLYCOPROTEIN; GLYCOPROTEIN IB; GLYCOPROTEIN IX; GLYCOPROTEIN V; LIPOCORTIN 5; PHOSPHATIDYLSERINE; PROSTAGLANDIN E1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BRIGHT FIELD MICROSCOPY; CALCIUM CELL LEVEL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FIBRIN FORMATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; PRIORITY JOURNAL; SHEAR FLOW; THROMBIN TIME; THROMBOCYTE ACTIVATION; VON WILLEBRAND DISEASE;

EID: 78751551208     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-262683     Document Type: Article

References (48)

1. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687-1693. (Pubitemid 47207163)
2. Cho J, Furie BC, Coughlin SR, Furie B. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest. 2008;118(3):1123-1131. (Pubitemid 351364619)
3. Gailani D, Renné T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost. 2007;5(6):1106-1112. (Pubitemid 46902107)
4. van der Meijden PE, Schoenwaelder SM, Cosemans JMEM, et al. Dual P2Y12 receptor signaling in thrombin-stimulated platelets: involvement of phosphoinositide 3-kinase beta but not gamma isoforms in Ca2+ mobilization and procoagulant activity. FEBS J. 2008;275(2):371-385.
5. Heemskerk JWM, Kuijpers MJE, Munnix ICA, Siljander PRM. Platelet collagen receptors and coagulation. A characteristic platelet response as possible target for antithrombotic treatment. Trends Cardiovasc Med. 2005;15(3):86-92.
6. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol. 2006;26(1):41-48. (Pubitemid 43732226)
7. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3(10):2185-2192.
8. Munnix ICA, Cosemans JMEM, Auger JM, Heemskerk JWM. Platelet response heterogeneity in thrombus formation. Thromb Haemost. 2009;102(6):1149-1156.
9. Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue-factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'. J Clin Invest. 1996;98(3):863-874.
10. Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb-IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res. 1998;90(6):247-258. (Pubitemid 28383786)
11. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res. 2007;120(suppl 1):S5-S9.
12. Lillicrap D. Von Willebrand disease: phenotype versus genotype, deficiency versus disease. Thromb Res. 2007;120(Suppl 1):S11-S16. (Pubitemid 46874547)
13. Béguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant activity requires GpIb-V-IX receptors and von Willebrand factor. Blood. 1999;93(2):564-570. (Pubitemid 29035737)
14. Keuren JFW, Ulrichts H, Feijge MAH, et al. Integrin alphaIIbbeta3 and shear-dependent action of glycoprotein Ibalpha stimulate platelet-dependent thrombin formation in stirred plasma. J Lab Clin Med. 2003;141(5):350-358.
15. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60(2):390-404.
16. Kawasaki T, Kaida T, Arnout J, Vermylen J, Hoylaerts MF. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic. Thromb Haemost. 1999;81(2):306-311. (Pubitemid 29078322)
17. Weeterings C, De Groot PG, Adelmeijer J, Lisman T. The glycoprotein Ib-V-IX complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood. 2008;112(8):3227-3233.
18. Dörmann D, Clemetson KJ, Kehrel B. The GpIb-V-IX thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood. 2000;96(7):2469-2478.
19. Hantgan RR, Hindriks G, Taylor RG, Sixma JJ, de Groot PG. Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb-IIIa are all involved in platelet adhesion to fibrin in flowing whole blood. Blood. 1990;76(2):345-353. (Pubitemid 20225525)
20. Endenburg SC, Hantgan RR, Lindeboom-Blokzijl L, et al. On the role of von Willebrand factor in promoting platelet adhesion to fibrin in flowing blood. Blood. 1995;86(11):4158-4165.
21. Weeterings C, Adelmeijer J, Myles T, de Groot PG, Lisman T. Glycoprotein Ibalpha-mediated platelet adhesion and aggregation to immobilized thrombin under conditions of flow. Arterioscler Thromb Vasc Biol. 2006;26(3):670-675.
22. Huizinga EG, Tsuji S, Romijn RA, et al. Structures of glycoprotein Ibα and its complex with von Willebrand factor A1 domain. Science. 2002;297(5584):1176-1179.
23. Cauwenberghs N, Ajzenberg N, Vauterin S, et al. Characterization of murine anti-glycoprotein Ib monoclonal antibodies that differentiate between shear-induced and ristocetin/botrocetin-induced glycoprotein Ib-von Willebrand factor interaction. Haemostasis. 2000;30(3):139-148.
24. Ulrichts H, Vanhoorelbeke K, Cauwenberghs S, et al. Von Willebrand factor but not alpha-thrombin binding to platelet glycoprotein Ibalpha is influenced by the HPA-2 polymorphism. Arterioscler Thromb Vasc Biol. 2003;23(7):1302-1307.
25. Keuren JFW, Wielders SJ, Ulrichts H, et al. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol. 2005;25(7):1499-1505.
26. Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Andersson LO, Meyer D. Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. Blood. 1987;70(5):1679-1682.
27. Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A. 2000;97(6):2803-2808. (Pubitemid 30159252)
28. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95(16):9524-9529.
29. Kinlough-Rathbone RL, Perry DW, Rand ML, Packham MA. Effects of cathepsin G pretreatment of platelets on their subsequent responses to aggregating agents. Thromb Res. 1999;95(6):315-323.
30. Bergmeier W, Rackebrandt K, Schroder W, Zirngibl H, Nieswandt B. Structural and functional characterization of the mouse von Willebrand factor receptor GpIb-V-IX/IX with novel monoclonal antibodies. Blood. 2000;95(3):886-893. (Pubitemid 30062710)
31. Stefanini L, Roden RC, Bergmeier W. CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood. 2009;114(12):2506-2514.
32. Munnix ICA, Strehl A, Kuijpers MJE, et al. The glycoprotein VI-phospholipase Cgamma2 signaling pathway controls thrombus formation induced by collagen and tissue factor in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2005;25(12):2673-2678.
33. Vanschoonbeek K, Wouters K, van der Meijden PEJ, et al. Anticoagulant effect of dietary fish oil in hyperlipidemia: an mRNA expression study in APOE2 knock-in mice. Arterioscler Thromb Vasc Biol. 2008;28(11):2023-2029.
34. Munnix ICA, Kuijpers MJE, Auger JM, et al. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol. 2007;27(11):2484-2490.
35. Vanschoonbeek K, Feijge MAH, van Kampen RJW, et al. Initiating and potentiating roles of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost. 2004;2(3):476-484.
36. Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. J Biol Chem. 2004;279(29):30697-30706. (Pubitemid 38938002)
37. Pidard D, Renesto P, Berndt MC, Rahbi S, Clemetson KJ, Chignard M. Neutrophil proteinase cathepsin G is proteolytically active on the human platelet glycoprotein Ib/IX receptor, characterization of the cleavage site within the glycoprotein Ibα subunit. Biochem J. 1994;303(Pt 2):489-498.
38. Renesto P, Si-Tahar M, Moniatte M, et al. Specific inhibition of thrombin-induced activation by the neutrophil proteinases elastase, cathepsin G, and proteinase 3: evidence for distinct cleavage sites within the aminoterminal domain of the thrombin receptor. Blood. 1997;89(6):1944-1953.
39. Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem. 2000;275(10):6819-6823. (Pubitemid 30146221)
40. Bergmeier W, Bouvard D, Eble JA, et al. Rhodocytin (aggretin) activates platelets lacking alpha2beta1 integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Ibalpha. J Biol Chem. 2001;276(27):25121-25126.
41. Keuren JF, Baruch D, Legendre P, et al. von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate. Blood. 2004;103(5):1741-1746.
42. Parker RI, Gralnick HR. Fibrin monomer induces binding of endogenous platelet von Willebrand factor to the glycocalicin portion of platelet glycoprotein Ib. Blood. 1987;70(5):1589-1594.
43. Vanhoorelbeke K, Ulrichts H, Van de Walle G, Fontayne A, Deckmyn H. Inhibition of platelet glycoprotein Ib and its antithrombotic potential. Curr Pharm Des. 2007;13(26):2684-2697. (Pubitemid 47430434)
44. Ruggeri ZM, Dent JA, Saldívar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood. 1999;94(1):172-178. (Pubitemid 29300146)
45. Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood. 2007;109(6):2424-2429.
46. Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mice. Thromb Haemost. 2008;99(2):264-270.
47. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6):1143-1156.
48. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIbbeta3 signaling in platelets. J Thromb Haemost. 2005;3(8):1752-1762.